In last trading session, Ambrx Biopharma Inc. (NASDAQ:AMAM) saw 0.33 million shares changing hands with its beta currently measuring -2.30. Company’s recent per share price level of $9.83 trading at $0.09 or 0.92% at ring of the bell on the day assigns it a market valuation of $620.76M. That closing price of AMAM’s stock is at a discount of -71.52% from its 52-week high price of $16.86 and is indicating a premium of 96.13% from its 52-week low price of $0.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.63 million shares which gives us an average trading volume of 888.19K if we extend that period to 3-months.
For Ambrx Biopharma Inc. (AMAM), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.36 in the current quarter.
Ambrx Biopharma Inc. (NASDAQ:AMAM) trade information
Upright in the green during last session for gaining 0.92%, in the last five days AMAM remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $9.83 price level, adding 4.19% to its value on the day. Ambrx Biopharma Inc.’s shares saw a change of 333.04% in year-to-date performance and have moved 9.34% in past 5-day. Ambrx Biopharma Inc. (NASDAQ:AMAM) showed a performance of 9.22% in past 30-days. Number of shares sold short was 2.33 million shares which calculate 1.23 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $22.86 to the stock, which implies a rise of 57.0% to its current value. Analysts have been projecting $9.00 as a low price target for the stock while placing it at a high target of $32.00. It follows that stock’s current price would drop -225.53% in reaching the projected high whereas dropping to the targeted low would mean a gain of 8.44% for stock’s current value.
Ambrx Biopharma Inc. (AMAM) estimates and forecasts
Statistics highlight that Ambrx Biopharma Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -24.38% of value to its shares in past 6 months, showing an annual growth rate of -255.17% while that of industry is 14.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. This year revenue growth is estimated to fall -78.00% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $570k for the same. And 6 analysts are in estimates of company making revenue of $310k in the next quarter that will end on Mar 2024.
In 2023, company’s earnings growth rate is likely to be around -370.75% while estimates for its earnings growth in next 5 years are of 21.70%.
Ambrx Biopharma Inc. is more likely to be releasing its next quarterly report in December and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Ambrx Biopharma Inc. (NASDAQ:AMAM)’s Major holders
Darwin Global Management, Ltd. is the top institutional holder at AMAM for having 16.69 million shares of worth $164.05 million. And as of Sep 29, 2023, it was holding 26.43% of the company’s outstanding shares.
The second largest institutional holder is Cormorant Asset Management, LP, which was holding about 9.92 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 15.71% of outstanding shares, having a total worth of $97.55 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Fidelity Select Portfolios – Health Care are the top two Mutual Funds which own company’s shares. As of Aug 30, 2023, the former fund manager was holding 1.3 million shares of worth $12.75 million or 2.05% of the total outstanding shares. The later fund manager was in possession of 0.35 million shares on Aug 30, 2023, making its stake of worth around $3.49 million in the company or a holder of 0.56% of company’s stock.